ADAMTS7 promoter methylation was marginally different in DOAC-treated AF patients from baseline to 28 days of treatment (15.2% vs. 13.9%, p = 0.044), Figure 3C. The gene discussed is ADAMTS7; the disease is atrial fibrillation.